Bell Investment Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bell Investment Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.07K	Hold	107	–	–	﹤0.01%	1517
2026 Q1	$1.02K	Hold	107	–	–	﹤0.01%	1540
2025 Q4	$835	Hold	107	–	–	﹤0.01%	1591
2025 Q3	$813	Hold	107	–	–	﹤0.01%	1616
2025 Q2	$959	Hold	107	–	–	﹤0.01%	1595
2025 Q1	$803	Hold	107	–	–	﹤0.01%	1624
2024 Q4	$805	Hold	107	–	–	﹤0.01%	1645
2024 Q3	$814	Hold	107	–	–	﹤0.01%	1657
2024 Q2	$662	Buy	+107	New	+$590	﹤0.01%	1722
2023 Q4	–	Sell	-132	Closed	-$935	–	1920
2023 Q3	$935	Buy	132 +9	+7%	+$65	﹤0.01%	1597
2023 Q2	$866	Hold	123	–	–	﹤0.01%	1634
2023 Q1	$1.03K	Buy	123 +2	+2%	+$19	﹤0.01%	1565
2022 Q4	$1.39K	Hold	121	–	–	﹤0.01%	1457
2022 Q3	$2K	Hold	121	–	–	﹤0.01%	1041
2022 Q2	$1K	Buy	+121	New	+$1.25K	﹤0.01%	1339

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Bell Investment Advisors's BCRX Position: Q2 2026 in Review

Bell Investment Advisors held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 107 shares worth $1.07K. The position accounts for ﹤0.01% of the portfolio, ranked #1517.

Bell Investment Advisors first reported a position in BCRX in Q2 2022 and has held it in 15 quarters since. The position peaked at $2K in Q3 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Bell Investment Advisors held 107 shares of BioCryst Pharmaceuticals worth $1.07K as of Q2 2026.
Bell Investment Advisors left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1517 holding.
Bell Investment Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2022 and has held it in 15 quarters since.
Bell Investment Advisors's BioCryst Pharmaceuticals position peaked at $2K in Q3 2022.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.